Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold ME, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJ, Schall TJ. Walters MJ, et al. Among authors: wright jj. J Pharmacol Exp Ther. 2010 Oct;335(1):61-9. doi: 10.1124/jpet.110.169714. Epub 2010 Jul 21. J Pharmacol Exp Ther. 2010. PMID: 20660125
1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
Pennell AM, Aggen JB, Sen S, Chen W, Xu Y, Sullivan E, Li L, Greenman K, Charvat T, Hansen D, Dairaghi DJ, Wright JJ, Zhang P. Pennell AM, et al. Among authors: wright jj. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1228-31. doi: 10.1016/j.bmcl.2013.01.005. Epub 2013 Jan 11. Bioorg Med Chem Lett. 2013. PMID: 23374868
World of Crayfish™: a web platform towards real-time global mapping of freshwater crayfish and their pathogens.
Ion MC, Bloomer CC, Bărăscu TI, Oficialdegui FJ, Shoobs NF, Williams BW, Scheers K, Clavero M, Grandjean F, Collas M, Baudry T, Loughman Z, Wright JJ, Ruokonen TJ, Chucholl C, Guareschi S, Koese B, Banyai ZM, Hodson J, Hurt M, Kaldre K, Lipták B, Fetzner JW, Cancellario T, Weiperth A, Birzaks J, Trichkova T, Todorov M, Balalaikins M, Griffin B, Petko ON, Acevedo-Alonso A, D'Elía G, Śliwińska K, Alekhnovich A, Choong H, South J, Whiterod N, Zorić K, Haase P, Soto I, Brady DJ, Haubrock PJ, Torres PJ, Şadrin D, Vlach P, Kaya C, Woo Jung S, Kim JY, Vermeersch XHC, Bonk M, Guiaşu R, Harlioğlu MM, Devlin J, Kurtul I, Błońska D, Boets P, Masigol H, Cabe PR, Jussila J, Vrålstad T, Beresford DV, Reid SM, Patoka J, Strand DA, Tarkan AS, Steen F, Abeel T, Harwood M, Auer S, Kelly S, Giantsis IA, Maciaszek R, Alvanou MV, Aksu Ö, Hayes DM, Kawai T, Tricarico E, Chakandinakira A, Barnett ZC, Kudor ŞG, Beda AE, Vîlcea L, Mizeranschi AE, Neagul M, Licz A, Cotoarbă AD, Petrusek A, Kouba A, Taylor CA, Pârvulescu L. Ion MC, et al. Among authors: wright jj. PeerJ. 2024 Oct 14;12:e18229. doi: 10.7717/peerj.18229. eCollection 2024. PeerJ. 2024. PMID: 39421415 Free PMC article.
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Simon N, Ley L, Cordes LM, Chandran E, Steinberg SM, Lee S, Lee MJ, Rastogi S, Sato N, Cao L, Banday AR, Boudjadi S, Merino MJ, Toubaji A, Akbulut D, Redd B, Bagheri H, Costello R, Gurram S, Agarwal PK, Chalfin HJ, Valera V, Streicher H, Wright JJ, Sharon E, Figg WD, Parnes HL, Gulley JL, Saraiya B, Pal SK, Quinn D, Stein MN, Lara PN, Bottaro DP, Mortazavi A. Apolo AB, et al. Among authors: wright jj. J Clin Oncol. 2024 Sep 1;42(25):3033-3046. doi: 10.1200/JCO.23.02233. Epub 2024 Jul 2. J Clin Oncol. 2024. PMID: 38954785 Free PMC article. Clinical Trial.
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
Gong J, Mita AC, Wei Z, Cheng HH, Mitchell EP, Wright JJ, Ivy SP, Wang V, Gray RC, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Alva AS, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gong J, et al. Among authors: wright jj. JCO Precis Oncol. 2024 Apr;8:e2300406. doi: 10.1200/PO.23.00406. JCO Precis Oncol. 2024. PMID: 38603651 Clinical Trial.
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
Gong J, Mita AC, Wei Z, Cheng HH, Mitchell EP, Wright JJ, Ivy SP, Wang V, Gray RC, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gong J, et al. Among authors: wright jj. JCO Precis Oncol. 2024 Apr;8:e2300407. doi: 10.1200/PO.23.00407. JCO Precis Oncol. 2024. PMID: 38603650 Clinical Trial.
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Connolly RM, Wang V, Hyman DM, Grivas P, Mitchell EP, Wright JJ, Sharon E, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Wang J, Wisinski KB, Tricoli JV, Conley BA, Harris LN, Arteaga CL, O'Dwyer PJ, Chen AP, Flaherty KT. Connolly RM, et al. Among authors: wright jj. Clin Cancer Res. 2024 Apr 1;30(7):1273-1280. doi: 10.1158/1078-0432.CCR-23-0633. Clin Cancer Res. 2024. PMID: 38433347 Free PMC article. Clinical Trial.
368 results